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Background. We have previously shown that CD8
depletion or CD34 selection of peripheral blood stem
cells (PBSC) reduced the incidence of acute graft-ver-
sus-host disease (GvHD) after nonmyeloablative stem-
cell transplantation (NMSCT). In this study, we ana-
lyze the effect of CD8 depletion or CD34 selection of
the graft on early T-cell reconstitution.
Methods. Nonmyeloablative conditioning regimen
consisted in 2 Gy total-body irradiation (TBI) alone, 2
Gy TBI and fludarabine, or cyclophosphamide and flu-
darabine. Patients 1 to 18 received unmanipulated
PBSC, patients 19 to 29 CD8-depleted PBSC, and pa-
tients 30 to 35 CD34-selected PBSC.
Results. T-cell counts, and particularly CD4 and
CD4CD45RA counts, remained low the first 6 months
after nonmyeloablative stem-cell transplantation
(NMSCT) in all patients. CD34 selection (P<0.0001) but
not CD8 depletion of PBSC significantly decreased T-
cell chimerism. Donor T-cell count was similar in un-
manipulated compared with CD8-depleted PBSC re-
cipients but was significantly lower in CD34-selected
PBSC recipients (P0.0012). T cells of recipient origin
remained stable over time in unmanipulated and CD8-
depleted PBSC patients but expanded in some CD34-
selected PBSC recipients between day 28 and 100 after
transplant. Moreover, whereas CD8 depletion only de-
creased CD8 counts (P<0.047), CD34 selection reduced
CD3(P<0.001), CD8 (P<0.016), CD4 (P<0.001), and
CD4CD45RA (P<0.001) cell counts. T-cell repertoire
was restricted in all patients on day 100 after hemato-
poietic stem-cell transplantation but was even more lim-
ited after CD34 selection (P0.002).
Conclusions. Despite of the persistence of a signifi-
cant number of T cells of recipient origin, T-cell counts
were low the first 6 months after NMSCT. Moreover,
contrary with CD8 depletion of the graft that only
affects CD8 lymphocyte counts, CD34 selection dra-
matically decreased both CD8 and CD4 counts.
Allogeneic hematopoietic stem-cell transplantation (allo-
HSCT) remains the only curative treatment for several he-
matologic malignancies (1). However, because of its toxicity,
this approach is restricted to younger and fitter patients.
Since the late 1970s, donor alloreactivity against tumor cells
has been recognized as a major factor in the success of allo-
HSCT (1). This graft-versus-leukemia (GvL) effect is so po-
tent that some leukemia relapses after standard allogeneic
transplantation can be effectively treated (70% long-term
complete remission in chronic myeloid leukemia) with donor
lymphocyte infusions (DLI) (2, 3). This observation led sev-
eral groups to set up new (less-toxic) transplant protocols
(NMSCT) based on a two-step approach: first, the use of
immunosuppressive (but nonmyeloablative) preparative reg-
imens providing sufficient immunosuppression to achieve
engraftment of allogeneic HSC and, in a second step, the
destruction of malignant cells by the GvL effect (4). On the
basis of extensive animal studies (5), the Seattle team has
proposed an original approach to NMSCT with a conditioning
regimen based on single-dose (2 Gy) total-body irradiation
(TBI)fludarabine (90 mg/m2), followed by posttransplant
immunosuppression with cyclosporine A (CsA) and mycophe-
nolate mofetil (MMF) that permitted the performance of the
transplant in an ambulatory care setting (5–7). The authors
observed a low transplant-related mortality (even in older
patients), which was most often attributed to graft-versus-
host disease (GvHD) or infections (6, 7). Thus, one major
objective to improve outcome following NMSCT is to achieve
rapid T-cell reconstitution (to permit the occurrence of the
GvL effect (8) and avoid opportunistic infections), without
severe GvHD.
T-cell depletion (TCD) of the graft has been associated with
a decreased incidence of GvHD (9). However, TCD can also
contribute to increased rates of graft failure as well as to
significant delays in immune reconstitution, leading to high
incidences of infection and leukemia relapse (9).
Several observations suggest that CD8 depletion could de-
crease the incidence of GvHD without compromising the GvL
effect after a standard allo-HSCT, at least for CML and
multiple myeloma patients (10–12). However, the impact of
CD8 depletion on immune recovery is not known. Similarly,
although several reports suggest that a strategy of TCD of
the graft followed by preemptive DLI may permit decrease in
the incidence of GvHD without impairing the GvL effect
(13–15), immune recovery after CD34-selected peripheral
blood stem-cell (PBSC) transplantation followed by preemp-
tive DLI is also largely unknown.
We previously showed that CD8 depletion or CD34 selec-
tion of PBSC apparently reduced the incidence of acute
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GvHD after NMSCT (16, 17). In this report, we analyzed




Fifty consecutive patients ineligible for a myeloablative allogeneic
HSCT were initially included. Fifteen patients were excluded from
the analysis of immune reconstitution because of early death (n10),
early graft rejection (n2), inadequate follow-up (n2), or bone
marrow instead of PBSC as stem-cell source (n1). Thus, 35 patients
with malignancies and a human leukocyte antigen (HLA)-identical
sibling (n17) or alternative donor (n18, 6 related 1-mismatch and
12 unrelated HLA-identical donors) were analyzed. Fifty-seven per-
cent of them had received a prior autotransplant (proportion not
significantly different among the groups). Their clinical characteris-
tics are summarized in Table 1. Donors received recombinant human
granulocyte colony-stimulating factor (G-CSF) (Neupogen, kindly
provided by Amgen, Brussels, Belgium) at 10 g/kg from day 5
through day 1 before transplant. Collection of PBSC was carried
out on days 1 and 0 using a continuous-flow blood-cell separator
(CS3000, Baxter-Fenwall Laboratories, Deerfield, IL, or Cobe
Spectra, Lakewood, CO) as previously reported (14, 16). The nonmy-
eloablative conditioning regimen consisted in 2 Gy TBI alone (n15),
2 Gy TBI and 90 mg/m2 fludarabine (previously untreated patients,
n13), or cyclophosphamide (3 g/m2) and fludarabine (90 mg/m2)
(patients who had previously received a full-dose TBI, n7). In the
context of a prospective comparative trial of NMSCT, patients 1 to 18
received unmanipulated PBSC, patients 19 to 29 CD8-depleted
PBSC, and patients 30 to 35 CD34-selected PBSC. Posttransplant
immunosuppression was carried out with CsA (from day 1 to day
120 or longer in case of alternative donor or chronic GvHD) and MMF
(15 mg/kg twice a day from day1 to day 28) as previously described
(18). At approximately day 40 posttransplantation, donors under-
went 12 to 16 L leukaphereses on 2 consecutive days to collect
lymphocytes. Patients 1 to 18 transplanted with unmanipulated
PBSC were assigned to receive unmanipulated preemptive DLI
(1107 and 2107 CD3 cells/kg at approximately days 40 and 80,
respectively), whereas patients 19 to 35 transplanted with CD8-
depleted or CD34-selected PBSC were assigned to receive CD8-
depleted DLI (1107 and 5107 CD3 cells/kg [2 in mismatched
transplants] per recipient at approximately days 40 and 80, respec-
tively). The first DLI was infused fresh, whereas the following were
cryopreserved and thawed. DLI were not to be given in case of an
antecedent grade III to IV acute GvHD or active GvHD at time of
scheduled infusions nor in recipients of unrelated transplants. Patients
with mixed chimerism (MC) on day 100 received a third DLI at approx-
imately day 120. CD34 selection and CD8 depletion of PBSC and DLI
were carried out with Nexell Isolex 300i (Nexell International, Wem-
mel, Belgium) as previously reported (14, 16). Written informed consent
was obtained from patients and donors, and our institution’s ethical
committee approved the protocol.
Clinical Management
The trigger values for red blood cell and platelet transfusion were 8.0
g/dL and 15109/L, respectively. G-CSF (5 g/kg per d) was adminis-
tered only when the granulocyte count was below 1.0109/L. The diag-
nosis and grading of acute GvHD was established as previously re-
ported (18, 19). Disease evaluation was routinely carried out on days 40,
100, 180, and 365. Polymerase chain reaction (PCR) for cytomegalovi-
rus (CMV) was performed weekly until day 100 and every 2 to 4 weeks
thereafter. Patients with a positive PCR received preemptive ganciclo-
vir for a minimum of 4 weeks and generally up to day 100.
TABLE 1. Characteristics of patients
Unmanipulated PBSC CD8-depleted PBSC CD34-selected PBSC
Number of patients 18 11 6
Age, Median (range) 58 (39–64) 57 (22–69) 62 (35–65)
Sex (male/female) 12/6 9/2 6/0
Disease at transplantation
NHL in CR 2 0 1
NHL not in CR 2 4 1
Metastatic RCC 3 0 1
Refractory multiple myeloma 3 2 1
HD in CR 0 1 1
AML in CR 2 2 0
CML in CP 1 1 0
CML in AP 1 1 0
Myelodysplastic syndrome 2 0 0
Myelofibrosis 1 0 0
Refractory CLL 1 0 1
Prior autologous HSCT (yes/no) 8/10 8/3 4/2
Donor type
HLA-identical sibling 9 4 4
Related with 1 HLA mismatch 2 2 2
HLA-identical unrelated 7 5 0
Conditioning regimen
2 Gy TBI 6 5 4
2 Gy TBIfludarabine 9 3 1
Fludarabinecyclophosphamide 3 3 1
180-day incidence of grade II-IV acute GvHD 50% 12% (P0.0025) 17% (P0.15)
1-yr probability of extensive chronic GvHD 57% 53% (NS) 58% (NS)
NHL, non-Hodgkin’s lymphoma; CR, complete response; RCC, renal-cell carcinoma; HD, Hodgkin’s disease; AML, acute myeloid leukemia;
CML, chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase; CLL, chronic lymphocytic leukemia; PBSC, peripheral blood stem
cell; HSCT, hematopoietic stem-cell transplantation; HLA, human leukocyte antigen; TBI, total-body irradiation; GvHD, graft-versus-host
disease.
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Laboratory Analyses on PBSC and DLI
Aliquots of the pooled PBSC as well as the CD8-depleted or CD34-
selected fractions were incubated with fluorescein isothiocyanate
(FITC)- or phycoerythrin (PE)-conjugated anti-CD34, CD3, CD4,
CD45RA, CD45RO, CD19, CD8, and CD56 monoclonal antibodies for
20 minutes at 20°C and were washed and fixed. A total of 1105 cells
per condition were analyzed using a FACS-scan analyzer (Becton-
Dickinson, San Jose, CA). The percentage of positive cells was de-
fined with dot-plot analysis using the whole nucleated cell popula-
tion. The percentage of positive cells in the isotype control was
subtracted from the positive-cell percentage to give the final percent-
age of positive cells. Data acquisition was performed with the
Cellquest software (Becton-Dickinson). Donor lymphocytes (before
and after CD8 depletion) were similarly examined using double
labeling with FITC- and PE-conjugated antibodies after treatment
with a lysing solution.
Chimerism Analysis
Chimerism among total peripheral blood white blood cells (WBC),
T cells, and myeloid cells as well as in unfractionated marrow was
assessed at days 28, 60, 100, and 180 after HSCT using fluorescence
in situ hybridization to detect X and Y chromosomes for recipients of
sex-mismatched transplants and PCR-based analysis of polymorphic
microsatellite regions for recipients of sex-matched transplants (16).
CD3 (T cells) and CD13/CD33 (myeloid cells) selection was carried
out with a FACStar Plus sorter (Becton-Dickinson) or with Ro-
setteSep (StemCell Technologies, Vancouver, Canada). MC was de-
fined as between 5% and 94% donor cells and full chimerism as 95%
or more of donor cells.
Immune Recovery
Patients’ peripheral WBC were examined on days 28, 42, 60, 80,
100, 120, and 180 using double labeling with FITC- and PE-conju-
gated antibodies before treatment with a lysing solution. Cell
subsets analyzed were T cells (CD3), CD4 lymphocytes, CD8
lymphocytes, CD4CD45RAhigh double-positive lymphocytes,
CD4CD45RO double-positive lymphocytes, CD56 cells, as well
as CD19 B lymphocytes. The percentage of positive cells was
defined with dot-plot analysis using the whole nucleated cell
population. The percentage of positive cells in the isotype control
was subtracted from the positive-cell percentage to give the final
percentage of positive cells. Each absolute cell subset count was
then calculated by multiplying this percentage by the absolute
nucleated cell count (determined by an Advia cell counter, Bayer,
Milan, Italy). Data acquisition was performed with the Cellquest
software (Becton-Dickinson). Lower and higher limits for each cell
subset were defined, respectively, as the 3rd and 97th percentile
of values obtained in 30 healthy blood donors.
Natural-Killer Activity Assay
PBMC were obtained by Ficoll (Nycomed Pharma SA, Oslo, Nor-
way) on days 28, 42, 60, 80, 100, 120, 140, 160, and 180 and were
tested for cytotoxicity against the natural killer (NK)-sensitive cell
line K562 in a 51Cr-release assay as previously described (20). Target
cells (K562) were labeled with 200 Ci 51Cr sodium chromate for 60
minutes, washed three times, and added at a concentration of 1105
cells per well to round-bottomed microtiter plates. Effector cells
(recipient PBMC) were added at effector:target ratios ranging from
50:1 to 1:1 in a final volume of 200 L per well. The plates were
incubated for 4 hours at 37°C in a humidified atmosphere with 5%
CO2. Maximum
51Cr release was ensured by addition of detergent
and spontaneous release by addition of complete medium to the
target cells. The culture supernatant was harvested after centrifu-
gation and counted in a gamma counter. All determinations were
performed in triplicate, and the percentage of specific lysis was
calculated as (Experimental cpmSpontaneous cpm)/(Maximum
cpmSpontaneous cpm)100. The NK activity was corrected by
dividing the percentage of specific lysis by the percentage of CD56
cells in the culture.
CDR3 Spectratyping
CDR3 spectratyping (immunoscope) was performed on day 100.
RNA was extracted from 10 to 30106 PBMC by Tripure (Roche,
Indianapolis, IN) according to the manufacturer’s protocol. First-
strand cDNA was generated from 2 g total RNA using 1st Strand
cDNA Synthesis Kit for reverse transcriptase-PCR (Roche) according
to the manufacturer’s protocol. Each TCR V segment was amplified
with one of the 24 V subfamily specific primers (V1-V24) and a
C primer conjugated to fluorescent dye 6-FAM (Applied Biosys-
tems, Lennik, Belgium) for CDR3 analysis (21). The size distribution
of each fluorescent PCR product was determined by electrophoresis
on an automated DNA sequencer (Applied Biosystems, Foster City,
CA), and data were analyzed by GeneScan-500 software (Perkin
Elmer Cetus Instruments, Emeryville, CA). The overall complexity
within a V subfamily was determined by counting the number of
peaks (intervals of 3 nucleotides without any gaps) per subfamily.
Normal complexity of subfamily was defined as consisting of at least
six peaks spaced three nucleotides apart without any gaps. The
overall spectratyping complexity (V score) was calculated as the
sum of the number of peaks in the 24 subfamilies.
Statistical Analyses
T-cell subset recovery as well as evolution of T-cell chimerism in
the CD8-depleted and CD34-selected groups were analyzed in com-
parison with the unmanipulated group by the two-way analysis of
variance test using graft manipulation and time as variables. Recov-
ery of CD3 cells of donor or recipient origin was calculated by
multiplying the CD3 cell count by the percentage of donor or host
T-cell chimerism, respectively. On the basis of the spectratype com-
plexity of five normal donors, we established a score of 176, based on
the 95% lower confidence interval, as the lower limit of normal.
Student’s t test was used to assess the difference in V score between
the normal donors and the patients. Spearman’s rank correlation
was used to examine the relationship between parameters. Statisti-
cal analyses were carried out with Graphpad Prism (Graphpad Soft-
ware, San Diego, CA).
RESULTS
Composition of the Graft
Patients 1 to 18 received unmanipulated PBSC containing
a median of 6.0 (0.8–14.9)106 CD34 cells/kg recipient, 321
(80–522)106 CD3 cells/kg, 196 (38–394)106 CD4 cells/
kg, 118 (43–178)106 CD8 cells/kg, and 63 (5–395)106
CD56 cells/kg, respectively. Patients 19 to 29 received CD8-
depleted PBSC containing a median of 5.4 (1.6–8.4)106
CD34 cells/kg, 88 (63–355)106 CD3 cells/kg, 69
(55–225)106 CD4 cells/kg, 2 (0.5–32)106 CD8 cells/kg,
and 28 (17–78)106 CD56 cells/kg, respectively. Patients 30
to 35 received CD34-selected PBSC containing a median of
5.5 (1.8–8.8)106 CD34 cells/kg, 0.07 (0.04–0.11)106
CD3 cells/kg, 0.03 (0.02–0.06)106 CD4 cells/kg, 0.04
(0.01–0.06)106 CD8 cells/kg, and 0.06 (0.04–0.09)106
CD56 cells/kg, respectively. The CD34 cell dose was sim-
ilar in the three groups, whereas the T-cell content obviously
differed significantly.
Clinical Data
The 180-day incidence of grade II to IV acute GvHD was
50% in the unmanipulated group, 12% in the CD8-depleted
group (P0.02), and 17% in the CD34-selected group
(P0.15, NS) (Table 1). The 180-day cumulative incidence of
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bacterial or fungal infection as well as the incidence of CMV
reactivation did not differ significantly among the three
groups (Fig. 1). The 180-day cumulative incidences of bacte-
rial and fungal infections were 46% and 28% in the unma-
nipulated group, 64% (NS) and 0% (NS) in the CD8-depleted
group, and 50% (NS) and 20% (NS) in the CD34-selected
group, respectively. For CMV-positive donor or recipient
pairs, the 180-day cumulative incidence of CMV reactivation
by PCR was 90% in the unmanipulated group, 83% in the
CD8-depleted group, and 50% in the CD34-selected group
(NS).
Recipient and Donor T Cells
The evolution of T-cell chimerism did not significantly dif-
fer between recipients of unmanipulated versus CD8-de-
pleted PBSC (Fig. 2A). However, CD34 selection of PBSC
significantly decreased CD3-cell chimerism (P0.0001)
(Fig. 2A). Median T-cell chimerisms in unmanipulated, CD8-
depleted, and CD34-selected recipients were 75% (13–98),
86% (16–100), and 23% (19–30) on day 28, 87% (37–100),
98% (28–100), and 32% (10–35) on day 100, and 90% (33–
100), 92% (1–100), and 78% (49–95) on day 180, respectively
(Fig. 2A). Donor T-cell counts were similar in unmanipulated
compared with CD8-depleted PBSC recipients but were sig-
nificantly lower in CD34-selected PBSC recipients
(P0.0012) (Fig. 2B). The T-cell count of recipient origin
remained stable over time in the unmanipulated and CD8-
depleted groups. However, CD34-selected PBSC recipients
had a higher CD3 cell count of host origin (P0.079) that
expanded between day 28 and 100 after the transplant (Fig.
2C). This was particularly demonstrative in a CMV-positive
patient who experienced CMV reactivation 20 days after a
CD34-selected NMSCT from a CMV-negative donor (Fig.
2D).
Lymphocyte Subset Evolution
The evolution of CD3, CD4, CD4CD45RA,
CD4CD45RO, CD8, and CD56 lymphocyte recovery in
unmanipulated, CD8-depleted, and CD34-selected trans-
plant recipients is shown in Figure 3. Counts of CD3
(P0.0053), CD4 (P0.0047), and CD4CD45RO
(P0.0120) cells increased with time, contrary with
CD4CD45RA cells (P0.23, NS) that remained stable.
CD8 depletion of PBSC significantly decreased number of
CD8 lymphocytes (P0.047) but not that of CD3, CD4,
CD4CD45RA, CD4CD45RO, CD56, and CD19 B
cells between day 28 and day 180 after NMSCT. CD34 selec-
tion significantly decreased numbers of CD3 cells (P0.001)
as well as CD8 (P0.016), CD4 (P0.001),
CD4CD45RA (P0.001), and CD4CD45RO (P0.013)
lymphocytes but not that of CD56 cells or CD19 lympho-
cytes. Moreover, contrary with CD34 selection of the graft
(P0.002), neither the type of nonmyeloablative conditioning
regimen nor the experience of a prior autologous transplant
significantly influenced the number of CD4CD45RA cells
on day 100 after NMSCT (Fig. 4). The same was true when
the analysis was restricted to the 18 patients receiving un-
manipulated PBSC. We also examined whether patient age,
donor type, occurrence of GvHD, or CMV reactivation af-
fected CD4 and CD8 cell counts (Fig. 5). Age did not
significantly impact on CD4 and CD8 counts. On the other
hand, patients who received transplants from an unrelated
donor had slightly lower CD4 counts (P0.023), probably
because they did not receive preemptive DLI. In addition,
both grade II to IV acute GvHD and CMV reactivation in-
creased the CD8 count (P0.029 and P0.001, respectively)
but did not affect the CD4 count (Fig. 5). The higher CD8
counts in patients with GvHD was probably caused by the
FIGURE 1. Cumulative incidence of (A) bacterial infections,
(B) fungal infections, and (C) cytomegalovirus (CMV) poly-
merase chain reaction (PCR) reactivation in the unmanipu-
lated (peripheral blood stem-cell [PBSC]), CD8-depleted
(CD8), and CD34-selected (CD34) groups. NMSCT, nonmy-
eloablative stem-cell transplantation.
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higher proportion of unmanipulated PBSC recipients in this
group, whereas the higher CD8 counts in patients with
CMV reactivation may by caused by CMV-specific CD8 T-cell
expansion. The 180-day probability of achieving normal
CD3, CD4, and CD4CD45RA cell counts were 52%,
52%, and 50% in the unmanipulated PBSC group, 58% (NS),
64% (NS), and 55% (NS) in the CD8-depleted PBSC group,
and 17% (NS), 0% (P0.059), and 0% (P0.043) in the CD34-
selected PBSC group.
Cytotoxic Activity Against K562
The cytotoxic activity of patients’ PBMC against K562 was
significantly higher in the CD8-depleted (P0.0142) and the
CD34-selected (P0.001) groups compared with the unma-
nipulated group. However, this probably reflects the higher
number of NK cells relative to the number of other lympho-
cytes in the tested PBMC from these patients. Indeed, when
the cytotoxic activity was corrected by the percentage of
CD56 cells in the culture, there was no more significant
differences of cytotoxic activity between the three groups
(Fig. 3G).
CD3 Spectratyping (V Score)
Figure 3H shows the comparison of complexity scores for
normal donors as well as 15 unmanipulated PBSC recipients,
9 CD8-depleted PBSC recipients, and 4 CD34-selected PBSC
recipients for whom adequate samples of day 100 PBMC
were available. The mean V score was 1885 for normal
donors versus 15718 for unmanipulated PBSC recipients
(P0.001), 14915 for CD8-depleted PBSC recipients (P0.001),
and 11530 for CD34-selected PBSC recipients (P0.018).
The V score in patients receiving transplants of CD34-
selected PBSC was significantly lower than in the other two
groups (P0.002 and 0.019) for comparisons with the PBSC
and CD8-depleted groups, respectively.
DISCUSSION
Previous studies have shown that T-cell reconstitution af-
ter myeloablative allogeneic transplantation is derived pri-
marily from expansion of mature T cells present in the stem-
cell graft and that CD45RO T cells predominate early after
the transplant (22, 23). Moreover, the T-cell repertoire was
shown to be markedly abnormal within the first months after
the transplant in all patients (24) but more particularly so in
recipients of T-cell depleted grafts (22, 24). However, little is
known about T-cell reconstitution after NMSCT. We per-
formed the present study to better define immune reconsti-
tution after NMSCT and to assess the impact of graft manip-
ulation (CD8 depletion or CD34 selection) on early T-cell
recovery.
Our study first evidenced that a significant number of T
cells of recipient origin persist at least 180 days after the
FIGURE 2. (A) Evolution of T-cell chimerism in the unmanipulated (PBSC), CD8-depleted (CD8), and CD34-selected (CD34)
groups. (B) Recovery of the CD3 lymphocytes of donor origin in the unmanipulated (PBSC), CD8-depleted (CD8), and
CD34-selected (CD34) groups. (C) Recovery of the CD3 lymphocytes of host origin in the unmanipulated and CD8-depleted
combined groups (PBSC and CD8) and CD34-selected (CD34) groups. (D) Recovery of host CD3 lymphocytes in a
CMV-positive patient receiving transplant of CD34-selected PBSC from a CMV-negative donor.
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transplant. Moreover, we showed than these recipient T cells
are able to expand, at least in some recipients of a CD34-
selected graft. This may represent less active graft-versus-
host reactivity in the absence of transplanted donor T cells.
Furthermore, this observation was particularly marked in a
CMV-positive patient who experienced CMV reactivation 20
days after a CD34-selected NMSCT from a CMV-negative
donor. It has been recently suggested that defense against
CMV infections among NMSCT recipients consisted of con-
tributions from both residual host memory immune re-
sponses and emerging donor graft-derived immunity (25).
The large increase of CD3 cells of host origin observed in
our patient shortly after CMV reactivation probably illus-
trates the generation of a host-derived anti-CMV immune
response. However, analysis of specific CMV CD4 and
CD8 cell reconstitution in the NMSCT setting is needed to
confirm this hypothesis (26). The persistence of recipient-
derived T cells and the demonstration that some of them can
FIGURE 3. (A–G) Recovery of the vari-
ous lymphocyte subsets and of cytotoxic
activity against K562 (natural-killer
[NK] activity) after NMSCT in the unma-
nipulated (PBSC), CD8-depleted (CD8),
and CD34-selected (CD34) groups. (hor-
izontal line) value of the third percentile
in 30 normal blood donors. (H) V com-
plexity score in normal controls versus
unmanipulated (PBSC), CD8-depleted
(CD8) or CD34-selected (CD34) PBSC
recipients.
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expand may explain the lower incidence of infections ob-
served the first months after NMSCT in comparison with
conventional allogeneic HSCT (25). In confirmation of this
hypothesis, a recent abstract by Maris et al. (27) showed that
CD4 cell counts were higher for NMSCT recipients com-
pared with myeloablative HSCT recipients on day 30 after
the allogeneic transplantation.
As observed after myeloablative HSCT, our results showed
that the CD56 cell count is the first to normalize after
unmanipulated NMSCT, followed by the CD8 lymphocyte
count. Busca et al. (28) compared immune reconstitution in
30 recipients of a myeloablative allogeneic HSCT with 14
NMSCT recipients conditioned with 2 Gy TBI and fludara-
bine. They observed that the absolute numbers of CD4,
CD8, CD45RO, CD4CD45RA, and CD56 cells were
similar in the two groups at any time after the transplant
and that CD4 cells remained below normal levels up to 1
year after the transplant in both groups. Similarly Maris et
al. (27) compared immune recovery in 68 recipients of a
myeloablative allogeneic HSCT with 51 NMSCT recipients
conditioned with 2 Gy TBI with or without fludarabine. They
evidenced that absolute CD4 cell counts were higher for
NMSCT compared with myeloablative transplants at day 30
but lower at day 365. Our results confirm that CD4 and
particularly naive CD4 (CD4CD45RA) cell counts re-
mained below normal for at least 6 months after the trans-
plant. In addition, whereas CD4 cells increased over time,
this progression was clearly caused by the expansion of mem-
ory (CD4CD45RO cells) and not to thymic generation of
new T cells because the count of CD4CD45RA cells did not
increase over time. Moreover, although two preliminary re-
ports have suggested that, compared with a standard my-
eloablative regimen, a nonmyeloablative conditioning regi-
men allowed for more rapid T-cell repertoire reconstitution
after allogeneic transplantation (29, 30), our results demon-
strate that the T-cell repertoire (V complexity score) on day
100 remained severely restricted in NMSCT recipients.
These defects may explain why the risk of late fungal and
viral infections is similar in NMSCT and conventional my-
eloablative transplant recipients (25).
This study also demonstrates that graft manipulation di-
rectly affects T-cell reconstitution. The recovery of NK and B
cells was not significantly influenced by graft manipulation.
CD8 depletion of PBSC reduced both CD3 and CD8 lym-
phocyte counts, whereas CD34-selected PBSC recipients had
very low counts of CD3, CD4, CD4CD45RA,
CD4CD45RO, and CD8 lymphocytes. In particular, the
speed of recovery of CD4 and CD4CD45 cells was similar
in the three groups, but after CD34 selection, patients
started with a much lower cell count at day 30, which ex-
plains the relative delay for full reconstitution. These obser-
vations suggest that, as observed in the myeloablative trans-
plant setting, early T-cell recovery after NMSCT depends
primarily on peripheral expansion of mature T cells given
with the graft. In addition, whereas CD8-depletion of PBSC
did not decrease the number of CD3 cells of donor origin,
CD34-selected PBSC recipients exhibited a drastically lower
number of such cells on day 100. This observation suggests
that the occurrence of a GvL effect could be seriously delayed
in patients receiving transplants of CD34-selected PBSC (8).
Surprisingly, we failed to demonstrate a higher incidence of
infection in the CD34-selected group. However, this is prob-
ably because of the relatively small number of patients (n6)
included in this group. Finally, we show that the V com-
plexity score was significantly lower in CD34-selected PBSC
recipients compared with unmanipulated PBSC recipients.
Because expansion of a few clones, particularly among CD8
cells, may hide the complexity in the same family, TCR
complexity might be even overestimated after CD34 selection
and even more so after CD8 depletion. On the other hand, it
has been recently shown that, after myeloablative HSCT, the
V complexity score was associated with the chimeric status
(22). We failed to find such an association in our patients.
In conclusion, our results show that, despite the persis-
tence of a significant number of T cells of recipient origin,
T-cell counts and particularly CD4 and CD4CD45RA cell
counts were low the first 6 months after NMSCT. Moreover,
contrary with CD8 depletion of PBSC that only affects CD8
lymphocyte counts, CD34 selection of PBSC dramatically
decreased both CD8 and CD4 counts. Because these obser-
vations may have important clinical applications in terms of
susceptibility to infections and occurrence of the GvL effect,
they need to be confirmed in a larger group of patients over
FIGURE 4. Comparison of day 100 counts of CD4CD45RA
cells according to (A) graft manipulation, (B) previous autol-
ogous HSCT, and (C) conditioning regimen.
BARON ET AL.December 27, 2003 1711
longer follow-up even if the differences are already well ap-
parent in our more modest series.
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